Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30127
Exploring the Safety of Sodium Glucose Co-Transporter-2 Inhibitors at the Imperial College London Diabetes Centre, UAE

Authors: Raad Nari, Maura Moriaty, Maha T. Barakat

Abstract:

Introduction: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new class of oral anti-diabetic drugs with a unique mechanism of action. They are used to improve glycaemic control in adults with type 2 diabetes by enhancing urinary glucose excretion. In the UAE, there has been certainly an increased use of these medications. As with any new medication, there are safety considerations related to their use in patients with type two diabetes. A retrospective study was conducted at the three main centres of the Imperial College London Diabetes Centre. Methodology: All patients in electronic database (Diamond) from October 2014 to October 2017 were included with a minimum of six months usage of sodium glucose co-transporter inhibitors that comprise canagliflozin, dapagliflozin and empagliflozin. There were 15 paired sample biochemical and clinical correlations. The analysis was done at the start of the study, three months and six months apart. SPSS version 24 was used for this study. Conclusion: This study of sodium glucose co-transporter-2 inhibitors used showed significant reductions in weight, glycated haemoglobin A1C, systolic and diastolic blood pressures. As the case with systematic reviews, there were similar changes in liver enzymes, raised total cholesterol, low density lipopoptein and high density lipoprotein. There was slight improvement in estimated glomerular filtration rate too. Our analysis also showed that they increased in the incidence of urinary tract symptoms and incidence of urinary tract infections.

Keywords: SGLT2 inhibitors dapagliflozin empagliflozin canagliflozin, adverse effects, amputation diabetic ketoacidosis DKA, urinary tract infection.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.2363169

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 291

References:


[1] Bashier, A., Khalifa, A. A., Rashid, F., Abdelgadir, E. I., Al Qaysi, A. A., Ali, R., … Alawadi, F. (2017). Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients with Type 2 Diabetes. Journal of Clinical Medicine Research, 9(6), 499–507. http://doi.org/10.14740/jocmr2976w(Accessed 26 Juy 2017).
[2] Wafic et al. (2016)`The effect of combined treatment with SGLT2 inhibitors and GLP1 agonists on weight and glycaemic control: analysis of data on 1688 patients with type 2 diabetes`, An Internet article, (Online), Available at: https://www.researchgate.net/profile/Nader_Lessan/publication/303236707_The_effect_of_combined_treatment_with_SGLT2_inhibitors_and_GLP1_agonists_on_ weight_and_glycaemic_control_analysis_of_data_on_1688_patients_with_type_2_diabetes/links /5739b74f08aea45ee83f6522/The-effect-of-combined-treatment-with-SGLT2-inhibitors-and-GLP1- agonists-on-weight-and-glycaemic-control-analysis-of-data-on-1688-patients-with-type-2- diabetes.pdf(Accessed 9 November2017).
[3] Bailey, C. J., Gross, J. L., Hennicken, D., Iqbal, N., Mansfield, T. A., & List, J. F. (2013). Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Medicine, 11, 43. http://doi.org/10.1186/1741-7015-11-43(Accessed 2 August 2017).
[4] FDA (2015) Sglt2 inhibitors: drug safety communication`, An Internet article, (Online), Available at: https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm475553.htm(Accessed 28 December 2017).
[5] Rosenwasser, R. F., Sultan, S., Sutton, D., Choksi, R., & Epstein, B. J. (2013). SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 6, 453–67. http://doi.org/10.2147/DMSO.S34416(Accessed 30 November 2017).
[6] Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., … Weir, M. R. (2016). American Association Of Clinical Endocrinologists And American College Of Endocrinology Position Statement On The Association Of Sglt-2 Inhibitors And Diabetic Ketoacidosis. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 22(6), 753–62. http://doi.org/10.4158/EP161292.PS(Accessed 12 December 2017).
[7] Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events - Full Text View - ClinicalTrials.gov. (n.d.). Retrieved October 29, 2017, from https://clinicaltrials.gov/ct2/show/NCT01730534(Accessed 29 October 2017
[8] Nauck, M. A., Del Prato, S., Durán-García, S., Rohwedder, K., Langkilde, A. M., Sugg, J., & Parikh, S. J. (2014). Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity & Metabolism, 16(11), 1111–20. http://doi.org/10.1111/dom.12327(Accessed 17 August 2017).
[9] Anderson, S. L. (2014). Dapagliflozin efficacy and safety: a perspective review. Therapeutic Advances in Drug Safety, 5(6), 242–254. http://doi.org/10.1177/2042098614551938 (Accessed 26 July 2017).
[10] AAFP (2015) FDA warns of diabetic ketoacidosis, uti with sglt2 inhibitors, An Internet Article, (Online), Available at:https://www.aafp.org/news/health-of-the-public/20151208sglt2inhibs.html(Accessed 28 December 2017).
[11] D’Elia, J., Segal, A., Bayliss, G., & Weinrauch, L. (2017). Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions. International Journal of Nephrology and Renovascular Disease, Volume 10, 153–158. http://doi.org/10.2147/IJNRD.S135899(Accessed 3 October 2017).